Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Alain Bouckenooghe"'
Autor:
Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Hao Wang, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe, Frederique Jantet-Blaudez, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 2107-2116 (2021)
The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who comp
Externí odkaz:
https://doaj.org/article/01e9265349dd42e8983c677b9b6022e8
Autor:
Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Jing Jin, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 3, Pp 523-529 (2020)
The tetravalent dengue vaccine (CYD-TDV; Dengvaxia®) is administered on a three-dose schedule, 6 months apart in those aged ≥9 years in a number of dengue-endemic countries in Asia and Latin America. In this study, CYD63 (NCT02824198), participant
Externí odkaz:
https://doaj.org/article/2620c153eb504ca4901aa9243abdbc49
Autor:
Ngoc Huu Tran, Danaya Chansinghakul, Chia Yin Chong, Chian Yong Low, Lynette P. Shek, Chan Quang Luong, Carina Frago, T. Anh Wartel, Sunny Sun, Anna Skipetrova, Alain Bouckenooghe
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 10, Pp 2315-2327 (2019)
Dengue is prevalent in the Asia-Pacific region. Participants of two immunogenicity and safety phase II studies conducted in Singapore and Vietnam (NCT0088089 and NCT00875524, respectively) were followed for up to four years after third vaccine dose o
Externí odkaz:
https://doaj.org/article/a0e26386e5e24f5cb85306817c238951
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 1, Pp 72-79 (2019)
The live-attenuated Japanese encephalitis chimeric virus vaccine JE-CV (IMOJEV®, Sanofi Pasteur) elicits a robust antibody response in children, which wanes over time. Clinical efficacy is based on a correlate of protection against JE infection defi
Externí odkaz:
https://doaj.org/article/efa34ff6b2394eb6bf09f30d73313032
Autor:
Kriengsak Limkittikul, Weerawan Hattasingh, Danaya Chansinghakul, Arunee Sabchareon, Wut Dulyachai, Carina Frago, T Anh Wartel, Edith Langevin, Sophia Gailhardou, Alain Bouckenooghe
Publikováno v:
Asian Pacific Journal of Tropical Medicine, Vol 12, Iss 9, Pp 396-403 (2019)
Objective: To investigate the long-term safety of a tetravalent dengue vaccine (CYD-TDV) in children in a phase Π b follow-up study in Thailand. Methods: In the phase Π b study, children aged 4-11 years were randomized (2:1) to receive three inject
Externí odkaz:
https://doaj.org/article/e0464c7186f04e73b6d1a922a29000c4
Autor:
Osamu Matsuoka, Dhaval M. Patel, Shin Sasaki, Hayato Oka, Toru Sasaki, Patricia J. Pietrobon, Thelma Laot, Alain Bouckenooghe, Josemund Menezes, Guy de Bruyn
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 2, Pp 322-328 (2018)
This was a randomized, placebo-controlled, Phase I/II study conducted in a Japanese cohort to assess the safety and immunogenicity of Clostridium difficile vaccine (the same formulation as that used in the ongoing global Phase III study). Healthy Jap
Externí odkaz:
https://doaj.org/article/9c3dc09bf2ee47019249f073ede3f0c2
Autor:
R Tedjo Sasmono, Anne-Frieda Taurel, Ari Prayitno, Hermin Sitompul, Benediktus Yohan, Rahma F Hayati, Alain Bouckenooghe, Sri Rezeki Hadinegoro, Joshua Nealon
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 12, Iss 6, p e0006616 (2018)
Dengue is a febrile illness transmitted by mosquitoes, causing disease across the tropical and sub-tropical world. Antibody prevalence data and serotype distributions describe population-level risk and inform public health decision-making.In this cro
Externí odkaz:
https://doaj.org/article/3208583388b54f1ab4683d2fcc84953d
Autor:
Ari Prayitno, Anne-Frieda Taurel, Joshua Nealon, Hindra Irawan Satari, Mulya Rahma Karyanti, Rini Sekartini, Soedjatmiko Soedjatmiko, Hartono Gunardi, Bernie Endyarni Medise, R Tedjo Sasmono, James Mark Simmerman, Alain Bouckenooghe, Sri Rezeki Hadinegoro
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 12, Iss 5, p e0006467 (2018)
[This corrects the article DOI: 10.1371/journal.pntd.0005621.].
Externí odkaz:
https://doaj.org/article/c33328c6501b4b74a0c7e48befc0f45d
Autor:
Ari Prayitno, Anne-Frieda Taurel, Joshua Nealon, Hindra Irawan Satari, Mulya Rahma Karyanti, Rini Sekartini, Soedjatmiko Soedjatmiko, Hartono Gunardi, Bernie Endyarni Medise, R Tedjo Sasmono, James Mark Simmerman, Alain Bouckenooghe, Sri Rezeki Hadinegoro
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 11, Iss 6, p e0005621 (2017)
BACKGROUND:Indonesia reports the second highest dengue disease burden in the world; these data are from passive surveillance reports and are likely to be significant underestimates. Age-stratified seroprevalence data are relatively unbiased indicator
Externí odkaz:
https://doaj.org/article/68b82edd5dae40b1916f1541cddf1043
Autor:
Joshua Nealon, Anne-Frieda Taurel, Maria Rosario Capeding, Ngoc Huu Tran, Sri Rezeki Hadinegoro, Tawee Chotpitayasunondh, Chee Kheong Chong, T Anh Wartel, Sophie Beucher, Carina Frago, Annick Moureau, Mark Simmerman, Thelma Laot, Maïna L'Azou, Alain Bouckenooghe
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 10, Iss 8, p e0004918 (2016)
Dengue incidence has increased globally, but empirical burden estimates are scarce. Prospective methods are best-able to capture all severities of disease. CYD14 was an observer-blinded dengue vaccine study conducted in children 2-14 years of age in
Externí odkaz:
https://doaj.org/article/53e23409321b40968f81795331d0361c